Hennion & Walsh Asset Management Inc. Lowers Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Hennion & Walsh Asset Management Inc. cut its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 46.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 5,167 shares of the company’s stock after selling 4,413 shares during the period. Hennion & Walsh Asset Management Inc.’s holdings in Neurocrine Biosciences were worth $705,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Sendero Wealth Management LLC lifted its holdings in Neurocrine Biosciences by 3.3% during the fourth quarter. Sendero Wealth Management LLC now owns 20,944 shares of the company’s stock valued at $2,859,000 after purchasing an additional 672 shares in the last quarter. Clarus Wealth Advisors purchased a new position in Neurocrine Biosciences during the fourth quarter valued at $253,000. Park Avenue Securities LLC lifted its holdings in Neurocrine Biosciences by 23.3% during the fourth quarter. Park Avenue Securities LLC now owns 7,080 shares of the company’s stock valued at $966,000 after purchasing an additional 1,336 shares in the last quarter. Tealwood Asset Management Inc. lifted its holdings in Neurocrine Biosciences by 1.0% during the fourth quarter. Tealwood Asset Management Inc. now owns 11,911 shares of the company’s stock valued at $1,626,000 after purchasing an additional 118 shares in the last quarter. Finally, Pallas Capital Advisors LLC lifted its holdings in Neurocrine Biosciences by 19.0% during the fourth quarter. Pallas Capital Advisors LLC now owns 7,673 shares of the company’s stock valued at $1,047,000 after purchasing an additional 1,225 shares in the last quarter. 92.59% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Neurocrine Biosciences

In other Neurocrine Biosciences news, CEO Kyle Gano sold 65,000 shares of Neurocrine Biosciences stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $141.50, for a total transaction of $9,197,500.00. Following the completion of the sale, the chief executive officer now directly owns 135,392 shares in the company, valued at $19,157,968. This trade represents a 32.44 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Ingrid Delaet sold 1,091 shares of Neurocrine Biosciences stock in a transaction dated Tuesday, December 17th. The shares were sold at an average price of $135.00, for a total transaction of $147,285.00. Following the sale, the insider now owns 2,507 shares of the company’s stock, valued at approximately $338,445. This represents a 30.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 68,694 shares of company stock worth $9,676,730 over the last three months. Insiders own 4.30% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on NBIX shares. William Blair reaffirmed an “outperform” rating on shares of Neurocrine Biosciences in a report on Monday, December 16th. HC Wainwright reaffirmed a “buy” rating and set a $190.00 price objective on shares of Neurocrine Biosciences in a report on Monday, December 16th. BMO Capital Markets decreased their price target on shares of Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating on the stock in a research note on Thursday, October 17th. UBS Group raised their price target on shares of Neurocrine Biosciences from $142.00 to $162.00 and gave the stock a “buy” rating in a research note on Wednesday, January 8th. Finally, Piper Sandler reissued an “overweight” rating and issued a $160.00 price target on shares of Neurocrine Biosciences in a research note on Monday, December 23rd. Five research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $164.81.

Neurocrine Biosciences Trading Up 0.9 %

Neurocrine Biosciences stock opened at $143.26 on Tuesday. Neurocrine Biosciences, Inc. has a 12-month low of $110.95 and a 12-month high of $157.98. The stock has a market cap of $14.51 billion, a P/E ratio of 38.41 and a beta of 0.33. The company has a 50-day moving average price of $132.17 and a 200 day moving average price of $131.15.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.